Highlights of antagonistic anti-CD40 mAb

• Superior affinity and in vivo efficacy of immune suppression as opposed to bleselumab. Bleselumab was chosen as the primary benchmark antibody.
• Fc effector null.
• Engineered with half-life extension to reduce frequency of clinical administration and improve patient compliance.
• Excellent physicochemical properties suitable for CMC development and high concentration formulation for subcutaneous administration.
• PCT formal application has been submitted in April 2023.
• Stage: preclinical, CMC to be initiated

In Vitro： YH015 has higher affinity for CD40

In Vivo：YH015 is superior in inhibition in the OVA antibody suppression screening experiment based on B-hCD40/FcRn double humanized mice

About CD40

CD40 is a transmembrane protein belonging to the tumor necrosis factor receptor (TNFR) superfamily, broadly expressed on antigen-presenting cells such as dendritic cells, macrophages, and B cells. It plays a crucial role in mediating immune responses by facilitating T cell activation, cytokine production, and the development of memory B cells. Engagement of CD40 with its natural ligand, CD40L (CD154), triggers a cascade of signaling events that promote inflammation and immune cell proliferation. Dysregulation of the CD40-CD40L pathway has been implicated in various autoimmune diseases, chronic inflammation, and cancer, making CD40 a promising therapeutic target. CD40 inhibitors aim to modulate this pathway, reducing pathological immune activation while preserving essential immune functions.

Learn more about the RenLite and ADC platform.